Citations (197)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (15)
Matthew Y. Bendikov, John O. Miners, Bradley S. Simpson, David J. Elliot, Susan J. Semple, David J. Claudie, Ross A. McKinnon, Elizabeth M. J. Gillam & Matthew J. Sykes. (2017) In vitro metabolism of the anti-inflammatory clerodane diterpenoid polyandric acid A and its hydrolysis product by human liver microsomes and recombinant cytochrome P450 and UDP-glucuronosyltransferase enzymes. Xenobiotica 47:6, pages 461-469.
Read now
Read now
Jolantha Beyerle, Eva Frei, Marie Stiborova, Nina Habermann & Cornelia M. Ulrich. (2015) Biotransformation of xenobiotics in the human colon and rectum and its association with colorectal cancer. Drug Metabolism Reviews 47:2, pages 199-221.
Read now
Read now
Eun-Sook Jeong, Yang-Weon Kim, Hyo-Ji Kim, Ho-Jung Shin, Jae-Gook Shin, Kwang Hee Kim, Yong Ha Chi, Soo Heui Paik & Dong-Hyun Kim. (2015) Glucuronidation of fimasartan, a new angiotensin receptor antagonist, is mainly mediated by UGT1A3. Xenobiotica 45:1, pages 10-18.
Read now
Read now
Bo Tan, Weimin Cai, Jinlian Zhang, Ning Zhou, Guo Ma, Ping Yang, Qing Zhu & Yizhun Zhu. (2014) Identification of UDP-glucuronosyltransferase isoforms responsible for leonurine glucuronidation in human liver and intestinal microsomes. Xenobiotica 44:9, pages 775-784.
Read now
Read now
Limei Ai, Liangliang Zhu, Lu Yang, Guangbo Ge, Yunfeng Cao, Yong Liu, Zhongze Fang & Yanyan Zhang. (2014) Selectivity for inhibition of nilotinib on the catalytic activity of human UDP-glucuronosyltransferases. Xenobiotica 44:4, pages 320-325.
Read now
Read now
Li Di. (2014) The role of drug metabolizing enzymes in clearance. Expert Opinion on Drug Metabolism & Toxicology 10:3, pages 379-393.
Read now
Read now
Christopher R. Gibson, Ping Lu, Cheri Maciolek, Christen Wudarski, Zoe Barter, Karen Rowland-Yeo, Mark Stroh, Eseng Lai & Deborah A. Nicoll-Griffith. (2013) Using human recombinant UDP-glucuronosyltransferase isoforms and a relative activity factor approach to model total body clearance of laropiprant (MK-0524) in humans. Xenobiotica 43:12, pages 1027-1036.
Read now
Read now
Tuomas Rahikainen, Merja R. Häkkinen, Moshe Finel, Markku Pasanen & Risto O. Juvonen. (2013) A high throughput assay for the glucuronidation of 7-hydroxy-4-trifluoromethylcoumarin by recombinant human UDP-glucuronosyltransferases and liver microsomes. Xenobiotica 43:10, pages 853-861.
Read now
Read now
Rui-Hua Dong, Zhong-Ze Fang, Liang-Liang Zhu, Guang-Bo Ge, Ling Yang & Ze-Yuan Liu. (2012) Identification of UDP-glucuronosyltransferase isoforms involved in hepatic and intestinal glucuronidation of phytochemical carvacrol. Xenobiotica 42:10, pages 1009-1016.
Read now
Read now
Miyoung Yoon, Jerry L. Campbell, Melvin E. Andersen & Harvey J. Clewell. (2012) Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results. Critical Reviews in Toxicology 42:8, pages 633-652.
Read now
Read now
Baojian Wu. (2011) Substrate inhibition kinetics in drug metabolism reactions. Drug Metabolism Reviews 43:4, pages 440-456.
Read now
Read now
Hiroshi Komura & Masahiro Iwaki. (2011) In vitro and in vivo small intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences. Drug Metabolism Reviews 43:4, pages 476-498.
Read now
Read now
Petra Jančová, Michal Šiller, Eva Anzenbacherová, Vladimír Křen, Pavel Anzenbacher & Vilím Šimánek. (2011) Evidence for differences in regioselective and stereoselective glucuronidation of silybin diastereomers from milk thistle (Silybum marianum) by human UDP-glucuronosyltransferases. Xenobiotica 41:9, pages 743-751.
Read now
Read now
Kathleen M Knights, Arduino A Mangoni & John O Miners. (2010) Defining the COX inhibitor selectivity of NSAIDs: implications for understanding toxicity. Expert Review of Clinical Pharmacology 3:6, pages 769-776.
Read now
Read now
Articles from other publishers (182)
John O. Miners, Thomas M. Polasek, Julie-Ann Hulin, Andrew Rowland & Robyn Meech. (2023) Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance. Pharmacology & Therapeutics 248, pages 108459.
Crossref
Crossref
Sara Bettonte, Mattia Berton, Felix Stader, Manuel Battegay & Catia Marzolini. (2023) Management of Drug Interactions with Inducers: Onset and Disappearance of Induction on Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyltransferase 1A1 Substrates. European Journal of Drug Metabolism and Pharmacokinetics.
Crossref
Crossref
Yingzi Li, Xiaoyan Liu, Ludi Li, Tao Zhang, Yadong Gao, Kewu Zeng & Qi Wang. (2023) Characterization of the metabolism of eupalinolide A and B by carboxylesterase and cytochrome P450 in human liver microsomes. Frontiers in Pharmacology 14.
Crossref
Crossref
Liangliang Zhu, Hui Lv, Ling Xiao, Yanyao Hou, Wenjuan Li, Guangbo Ge & Chunzhi Ai. (2023) Diverse effects of α-/β-estradiol on catalytic activities of human UDP-glucuronosyltransferases (UGT). The Journal of Steroid Biochemistry and Molecular Biology 225, pages 106196.
Crossref
Crossref
Jinqian Chen, Hao Zhang, Xia Hu, Mengyuan Xu, Yanjun Su, Chunze Zhang, Yuan Yue, Xiaomin Zhang, Xinyu Wang, Wei Cui, Zhenyu Zhao & Xichuan Li. (2022) Phloretin exhibits potential food-drug interactions by inhibiting human UDP-glucuronosyltransferases in vitro. Toxicology in Vitro 84, pages 105447.
Crossref
Crossref
Zhe Wang, Lili Jiang, Xiaoyu Wang, Hang Yin, Zhen Wang, Xin Lv & Yong Liu. (2022)
Cabozantinib Carries the Risk of Drug-Drug Interactions
via
Inhibition of UDPglucuronosyltransferase
(UGT) 1A9
. Current Drug Metabolism 23:11, pages 912-919.
Crossref
Crossref
Fan Yang, Sijie Liu, Gerhard Wolber, Matthias Bureik & Maria Kristina Parr. (2022) Complete Reaction Phenotyping of Propranolol and 4-Hydroxypropranolol with the 19 Enzymes of the Human UGT1 and UGT2 Families. International Journal of Molecular Sciences 23:13, pages 7476.
Crossref
Crossref
Xichuan Li, Ce Wang, Jinqian Chen, Xia Hu, Hao Zhang, Zhiying Li, Bei Lan, Wei Zhang, Yanjun Su & Chunze Zhang. (2022) Potential interactions among myricetin and dietary flavonols through the inhibition of human UDP-glucuronosyltransferase in vitro. Toxicology Letters 358, pages 40-47.
Crossref
Crossref
Amin Alibakhshi & Bernd Hartke. (2022) Implicitly perturbed Hamiltonian as a class of versatile and general-purpose molecular representations for machine learning. Nature Communications 13:1.
Crossref
Crossref
Verawan Uchaipichat, Andrew Rowland & John O. Miners. (2022) Inhibitory effects of non-steroidal anti-inflammatory drugs on human liver microsomal morphine glucuronidation: Implications for drug-drug interaction liability. Drug Metabolism and Pharmacokinetics 42, pages 100442.
Crossref
Crossref
Mariamena Arbitrio, Francesca Scionti, Maria Teresa Di Martino, Licia Pensabene, Pierfrancesco Tassone & Pierosandro Tagliaferri. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
657
697
.
Kazuya Maeda, Akihiro Hisaka, Kiyomi Ito, Yoshiyuki Ohno, Akihiro Ishiguro, Reiko Sato & Naomi Nagai. (2021) Classification of drugs for evaluating drug interaction in drug development and clinical management. Drug Metabolism and Pharmacokinetics 41, pages 100414.
Crossref
Crossref
Yawen Yuan, Jun Zhang, Boyu Fang, Xiaoqiang Xiang, Guo Ma, Shunguo Zhang, Bin Zhu & Weimin Cai. (2021) A Novel Method for Predicting the Human Inherent Clearance and Its Application in the Study of the Pharmacokinetics and Drug–Drug Interaction between Azidothymidine and Fluconazole Mediated by UGT Enzyme. Pharmaceutics 13:10, pages 1734.
Crossref
Crossref
Zhe Wang, Xiaoyu Wang, Zhen Wang, Yaqin Jia, Yuyi Feng, Lili Jiang, Yangliu Xia, Jun Cao & Yong Liu. (2021) In vitro inhibition of human UDP-glucuronosyltransferase (UGT) 1A1 by osimertinib, and prediction of in vivo drug-drug interactions. Toxicology Letters 348, pages 10-17.
Crossref
Crossref
Xiaoyu Wang, Zhe Wang, Xiaoyu Fan, Mingrui Yan, Lili Jiang, Yangliu Xia, Jun Cao & Yong Liu. (2021) Comparison of the drug-drug interactions potential of ibrutinib and acalabrutinib via inhibition of UDP-glucuronosyltransferase. Toxicology and Applied Pharmacology 424, pages 115595.
Crossref
Crossref
Yazun Jarrar & Su-Jun Lee. (2021) The Functionality of UDP-Glucuronosyltransferase Genetic Variants and their Association with Drug Responses and Human Diseases. Journal of Personalized Medicine 11:6, pages 554.
Crossref
Crossref
Rui Zhang, Ye Wei, Tingyu Yang, Xixi Huang, Jinping Zhou, Chunxiao Yang, Jiani Zhou, Yani Liu & Shaojun Shi. (2021) Inhibitory effects of quercetin and its major metabolite quercetin‑3‑O‑β‑D‑glucoside on human UDP‑glucuronosyltransferase 1A isoforms by liquid chromatography‑tandem mass spectrometry. Experimental and Therapeutic Medicine 22:2.
Crossref
Crossref
Zhenxing Wu, Dejun Jiang, Jike Wang, Chang-Yu Hsieh, Dongsheng Cao & Tingjun Hou. (2021) Mining Toxicity Information from Large Amounts of Toxicity Data. Journal of Medicinal Chemistry 64:10, pages 6924-6936.
Crossref
Crossref
Qi-Hang Zhou, Xia Lv, Zhen-Hao Tian, Moshe Finel, Lei Feng, Peng-Chao Huo, Ya-Di Zhu, Yin Lu, Jie Hou & Guang-Bo Ge. (2021) A fluorescence-based microplate assay for high-throughput screening and evaluation of human UGT inhibitors. Analytica Chimica Acta 1153, pages 338305.
Crossref
Crossref
Caroline Sychterz, Aleksandra Galetin & Kunal S. Taskar. (2021) When special populations intersect with drug–drug interactions: Application of physiologically‐based pharmacokinetic modeling in pregnant populations. Biopharmaceutics & Drug Disposition 42:4, pages 160-177.
Crossref
Crossref
Xiaoyu Wang, Zhe Wang, Zhen Wang, Xiuyuan Chen, Hang Yin, Lili Jiang, Jun Cao & Yong Liu. (2021) Inhibition of human UDP-glucuronosyltransferase enzyme by belinostat: Implications for drug-drug interactions. Toxicology Letters 338, pages 51-57.
Crossref
Crossref
John O. Miners, Andrew Rowland, Jonathan J. Novak, Kimberly Lapham & Theunis C. Goosen. (2021) Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotyping. Pharmacology & Therapeutics 218, pages 107689.
Crossref
Crossref
Hu Tingting, Shi Xianbao, Jiayin Hu & Yang Jingming. (2021) Species Difference of Asarinin Metabolism in vitro and its Effect on the Activity of Cytochrome P450 Enzymes. Pharmacognosy Magazine 17:76, pages 759.
Crossref
Crossref
Jin Zhou, Upendra A. Argikar & John O. Miners. 2021. Enzyme Kinetics in Drug Metabolism. Enzyme Kinetics in Drug Metabolism
301
338
.
Zifei Qin, Mengmeng Jia, Jing Yang, Han Xing, Zhao Yin, Zhihong Yao, Xiaojian Zhang & Xinsheng Yao. (2020) Multiple circulating alkaloids and saponins from intravenous Kang-Ai injection inhibit human cytochrome P450 and UDP-glucuronosyltransferase isozymes: potential drug–drug interactions. Chinese Medicine 15:1.
Crossref
Crossref
Pramod C. Nair, Nuy Chau, Ross A. McKinnon & John O. Miners. (2020) Arginine-259 of UGT2B7 Confers UDP-Sugar Selectivity. Molecular Pharmacology 98:6, pages 710-718.
Crossref
Crossref
Kimberly Lapham, Ernesto Callegari, Julie Cianfrogna, Jian Lin, Mark Niosi, Christine C. Orozco, Raman Sharma & Theunis C. Goosen. (2020) In Vitro Characterization of Ertugliflozin Metabolism by UDP-Glucuronosyltransferase and Cytochrome P450 Enzymes. Drug Metabolism and Disposition 48:12, pages 1350-1363.
Crossref
Crossref
Yan Rong & Tony K L Kiang. (2020) Characterizations of Human UDP-Glucuronosyltransferase Enzymes in the Conjugation of p-Cresol. Toxicological Sciences 176:2, pages 285-296.
Crossref
Crossref
David Busse, Sara Leandersson, Sara Amberntsson, Malin Darnell & Constanze Hilgendorf. (2020) Industrial Approach to Determine the Relative Contribution of Seven Major UGT Isoforms to Hepatic Glucuronidation. Journal of Pharmaceutical Sciences 109:7, pages 2309-2320.
Crossref
Crossref
Zhe Wang, Xiaoyu Wang, Yaqin Jia, Hang Yin, Yuyi Feng, Lili Jiang, Jun Cao & Yong Liu. (2020) Inhibition of human UDP‐glucuronosyltransferase enzymes by midostaurin and ruxolitinib: implications for drug–drug interactions. Biopharmaceutics & Drug Disposition 41:6, pages 231-238.
Crossref
Crossref
Akihiro Ishiguro, Reiko Sato & Naomi Nagai. (2020) Development of a new Japanese guideline on drug interaction for drug development and appropriate provision of information. Drug Metabolism and Pharmacokinetics 35:1, pages 12-17.
Crossref
Crossref
Aprajita S. Yadav, Nina R. Shah, Timothy J. Carlson & James P. Driscoll. (2019)
Metabolite Profiling and Reaction Phenotyping for the
in Vitro
Assessment of the Bioactivation of Bromfenac
. Chemical Research in Toxicology 33:1, pages 249-257.
Crossref
Crossref
Ren-Jong Liang, Yin-Ning Shih, Yen-Lun Chen, Wei-Yang Liu, Wan-Ling Yang, Shih-Yu Lee & Hong-Jaan Wang. (2020) A dual system platform for drug metabolism: Nalbuphine as a model compound. European Journal of Pharmaceutical Sciences 141, pages 105093.
Crossref
Crossref
Ravindra Varma Alluri & Manthena V.S. Varma. 2020. Identification and Quantification of Drugs, Metabolites, Drug Metabolizing Enzymes, and Transporters. Identification and Quantification of Drugs, Metabolites, Drug Metabolizing Enzymes, and Transporters
609
631
.
Zhenxing Wu, Tailong Lei, Chao Shen, Zhe Wang, Dongsheng Cao & Tingjun Hou. (2019) ADMET Evaluation in Drug Discovery. 19. Reliable Prediction of Human Cytochrome P450 Inhibition Using Artificial Intelligence Approaches. Journal of Chemical Information and Modeling 59:11, pages 4587-4601.
Crossref
Crossref
Porntipa Korprasertthaworn, Nuy Chau, Pramod C. Nair, Andrew Rowland & John O. Miners. (2019) Inhibition of human UDP-glucuronosyltransferase (UGT) enzymes by kinase inhibitors: Effects of dabrafenib, ibrutinib, nintedanib, trametinib and BIBF 1202. Biochemical Pharmacology 169, pages 113616.
Crossref
Crossref
Sinjini Sikdar, Roby Joehanes, Bonnie R Joubert, Cheng-Jian Xu, Marta Vives-Usano, Faisal I Rezwan, Janine F Felix, James M Ward, Weihua Guan, Rebecca C Richmond, Jennifer A Brody, Leanne K Küpers, Nour Baïz, Siri E Håberg, Jennifer A Smith, Sarah E Reese, Stella Aslibekyan, Cathrine Hoyo, Radhika Dhingra, Christina A Markunas, Tao Xu, Lindsay M Reynolds, Allan C Just, Pooja R Mandaviya, Akram Ghantous, Brian D Bennett, Tianyuan Wang, The BIOS Consortium, Kelly M Bakulski, Erik Melen, Shanshan Zhao, Jianping Jin, Zdenko Herceg, Joyce van Meurs, Jack A Taylor, Andrea A Baccarelli, Susan K Murphy, Yongmei Liu, Monica Cheng Munthe-Kaas, Ian J Deary, Wenche Nystad, Melanie Waldenberger, Isabella Annesi-Maesano, Karen Conneely, Vincent WV Jaddoe, Donna Arnett, Harold Snieder, Sharon LR Kardia, Caroline L Relton, Ken K Ong, Susan Ewart, Hortensia Moreno-Macias, Isabelle Romieu, Nona Sotoodehnia, Myriam Fornage, Alison Motsinger-Reif, Gerard H Koppelman, Mariona Bustamante, Daniel Levy & Stephanie J London. (2019) Comparison of smoking-related DNA methylation between newborns from prenatal exposure and adults from personal smoking. Epigenomics 11:13, pages 1487-1500.
Crossref
Crossref
Deok-Kyu Hwang, Ju-Hyun Kim, Yongho Shin, Won-Gu Choi, Sunjoo Kim, Yong-Yeon Cho, Joo Young Lee, Han Chang Kang & Hye Suk Lee. (2019) Identification of Catalposide Metabolites in Human Liver and Intestinal Preparations and Characterization of the Relevant Sulfotransferase, UDP-glucuronosyltransferase, and Carboxylesterase Enzymes. Pharmaceutics 11:7, pages 355.
Crossref
Crossref
Nuy Chau, Leyla Kaya, Benjamin C. Lewis, Peter I. Mackenzie & John O. Miners. (2019)
Drug and Chemical Glucosidation by Control Supersomes and Membranes from
Spodoptera frugiperda
(Sf) 9 Cells: Implications for the Apparent Glucuronidation of Xenobiotics by UDP-glucuronosyltransferase 1A5
. Drug Metabolism and Disposition 47:3, pages 271-278.
Crossref
Crossref
Justine Badée, Stephen Fowler, Saskia N. de Wildt, Abby C. Collier, Stephan Schmidt & Neil Parrott. (2018) The Ontogeny of UDP-glucuronosyltransferase Enzymes, Recommendations for Future Profiling Studies and Application Through Physiologically Based Pharmacokinetic Modelling. Clinical Pharmacokinetics 58:2, pages 189-211.
Crossref
Crossref
Emilio S. Petito, David J.R. Foster, Michael B. Ward & Matthew J. Sykes. (2019) Molecular Modeling Approaches for the Prediction of Selected Pharmacokinetic Properties. Current Topics in Medicinal Chemistry 18:26, pages 2230-2238.
Crossref
Crossref
Xia Lv, Jian‐Bin Zhang, Jie Hou, Tong‐Yi Dou, Guang‐Bo Ge, Wen‐Zhong Hu & Ling Yang. (2018) Chemical Probes for Human UDP‐Glucuronosyltransferases: A Comprehensive Review. Biotechnology Journal 14:1.
Crossref
Crossref
Niladri Chattopadhyay, Tobias Kanacher, Manuela Casjens, Sebastian Frechen, Sandra Ligges, Torsten Zimmermann, Antje Rottmann, Bart Ploeger, Joachim Höchel & Marcus‐Hillert Schultze‐Mosgau. (2018) CYP3A4‐mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1‐mediated effects on bilirubin glucuronidation in humans. British Journal of Clinical Pharmacology 84:12, pages 2857-2866.
Crossref
Crossref
Seong Eun JinHyekyung HaHyeun-Kyoo Shin. (2018)
Effects of Herbal Formulas
Bojungikgi-tang
and
Palmijihwang-hwan
on Inflammation in RAW 264.7 Cells and the Activities of Drug-Metabolizing Enzymes in Human Hepatic Microsomes
. Journal of Medicinal Food 21:11, pages 1173-1187.
Crossref
Crossref
Anna Mróz, Izabela Ryska, Hanna Sominko, Anna Bejrowska & Zofia Mazerska. (2018) Drug-drug interaction potential of antitumor acridine agent C-1748: The substrate of UDP-glucuronosyltransferases 2B7, 2B17 and the inhibitor of 1A9 and 2B7. Pharmacological Reports 70:5, pages 972-980.
Crossref
Crossref
Jung Bae Park, Doyun Kim, Jee Sun Min, Su Jeong, Doo-Yeoun Cho, Yu Fen Zheng, Kee Dong Yoon & Soo Kyung Bae. (2018) Identification and characterization of in vitro inhibitors against UDP-glucuronosyltransferase 1A1 in uva-ursi extracts and evaluation of in vivo uva-ursi-drug interactions. Food and Chemical Toxicology 120, pages 651-661.
Crossref
Crossref
Tony K. L. Kiang. (2018) Clinical Pharmacokinetics and Drug–Drug Interactions of Elbasvir/Grazoprevir. European Journal of Drug Metabolism and Pharmacokinetics 43:5, pages 509-531.
Crossref
Crossref
Chen Xu, Jie Gao, Hai-Feng Zhang, Na Gao, Yuan-yuan Guo, Yan Fang, Qiang Wen & Hai-Ling Qiao. (2018) Content and Activities of UGT2B7 in Human Liver In Vitro and Predicted In Vivo: A Bottom-Up Approach. Drug Metabolism and Disposition 46:9, pages 1351-1359.
Crossref
Crossref
Seong Eun Jin, Hyeun-Kyoo Shin & Hyekyung Ha. (2018) Inhibitory potential of three Yin-tonification herbal formulas on the activities of human major cytochrome P450 and UDP- glucuronosyltransferases isozymes in vitro. Journal of Traditional Chinese Medicine 38:4, pages 511-522.
Crossref
Crossref
Juan Román, Antonio Castillo, Luis Cottet & Andrea Mahn. (2018) Kinetic and structural study of broccoli myrosinase and its interaction with different glucosinolates. Food Chemistry 254, pages 87-94.
Crossref
Crossref
Ying Peng, Xueyuan Zhang, Yinci Zhu, Hui Wu, Shiyin Gu, Qingqing Chang, Yi Zhou, Guangji Wang & Jianguo Sun. (2018) Atypical Kinetics and Albumin Effect of Glucuronidation of 5-n-Butyl-4-{4-[2-(1H-tetrazole-5- yl)-1H-pyrrol-1-yl]phenylmethyl}-2,4-dihydro-2-(2,6- dichlorophenyl)-3H-1,2,4-triazol-3-one, a Novel Nonpeptide Angiotensin Type 1 Receptor Antagonist, in Liver Microsomes and UDP-Glucuronosyl-transferase. Molecules 23:3, pages 688.
Crossref
Crossref
Xia Lv, Jian-Bin Zhang, Xin-Xin Wang, Wen-Zhong Hu, Yu-Sheng Shi, Shu-Wen Liu, Da-Cheng Hao, Wei-Dong Zhang, Guang-Bo Ge, Jie Hou & Ling Yang. (2018) Amentoflavone is a potent broad-spectrum inhibitor of human UDP-glucuronosyltransferases. Chemico-Biological Interactions 284, pages 48-55.
Crossref
Crossref
John O. Miners, Attarat Pattanawongsa & Andrew Rowland. (2018)
Response to
in vitro
and physiologically-based pharmacokinetic assessment of the drug-drug interaction potential of canagliflozin
. British Journal of Clinical Pharmacology 84:2, pages 392-393.
Crossref
Crossref
Verawan Uchaipichat. (2018) In vitro inhibitory effects of major bioactive constituents of Andrographis paniculata, Curcuma longa and Silybum marianum on human liver microsomal morphine glucuronidation: A prediction of potential herb-drug interactions arising from andrographolide, curcumin and silybin inhibition in humans. Drug Metabolism and Pharmacokinetics 33:1, pages 67-76.
Crossref
Crossref
Martin Perreault, Ewa Wunsch, Andrzej Białek, Jocelyn Trottier, Mélanie Verreault, Patrick Caron, Guy G. Poirier, Piotr Milkiewicz & Olivier Barbier. (2018) Urinary Elimination of Bile Acid Glucuronides under Severe Cholestatic Situations: Contribution of Hepatic and Renal Glucuronidation Reactions. Canadian Journal of Gastroenterology and Hepatology 2018, pages 1-12.
Crossref
Crossref
Satheeshkumar Nanjappan, David Paul & Lavanya Bolla. 2018.
283
322
.
R. Meech, D.-G. Hu, J.O. Miners & P.I. Mackenzie. 2018. Comprehensive Toxicology. Comprehensive Toxicology
468
496
.
Niloufar Marsousi, Jules A. Desmeules, Serge Rudaz & Youssef Daali. (2018) Prediction of drug-drug interactions using physiologically-based pharmacokinetic models of CYP450 modulators included in Simcyp software. Biopharmaceutics & Drug Disposition 39:1, pages 3-17.
Crossref
Crossref
Brahim Achour, Alyssa Dantonio, Mark Niosi, Jonathan J. Novak, John K. Fallon, Jill Barber, Philip C. Smith, Amin Rostami-Hodjegan & Theunis C. Goosen. (2017) Quantitative Characterization of Major Hepatic UDP-Glucuronosyltransferase Enzymes in Human Liver Microsomes: Comparison of Two Proteomic Methods and Correlation with Catalytic Activity. Drug Metabolism and Disposition 45:10, pages 1102-1112.
Crossref
Crossref
Huma Mehboob, Imtiaz Mahmood Tahir, Tahir Iqbal, Naheed Akhter, Naveed Munir & Muhammad Riaz. 2017. Genetic Polymorphisms. Genetic Polymorphisms.
JO Miners, X Yang, KM Knights & L Zhang. (2017) The Role of the Kidney in Drug Elimination: Transport, Metabolism, and the Impact of Kidney Disease on Drug Clearance. Clinical Pharmacology & Therapeutics 102:3, pages 436-449.
Crossref
Crossref
Na Yang, Runbin Sun, Xiaoying Liao, Jiye Aa & Guangji Wang. (2017) UDP-glucuronosyltransferases (UGTs) and their related metabolic cross-talk with internal homeostasis: A systematic review of UGT isoforms for precision medicine. Pharmacological Research 121, pages 169-183.
Crossref
Crossref
Yan Lou, Wenqi Qiu, Zhe Wu, Qian Wang, Yunqing Qiu & Su Zeng. (2017) Mass spectral analysis of the multikinase inhibitor BZG and its metabolites and analysis of their binding to vascular endothelial growth factor receptor-2. Oncotarget 8:18, pages 29951-29962.
Crossref
Crossref
John O. Miners, Nuy Chau, Andrew Rowland, Kushari Burns, Ross A. McKinnon, Peter I. Mackenzie, Geoffrey T. Tucker, Kathleen M. Knights & Ganessan Kichenadasse. (2017) Inhibition of human UDP-glucuronosyltransferase enzymes by lapatinib, pazopanib, regorafenib and sorafenib: Implications for hyperbilirubinemia. Biochemical Pharmacology 129, pages 85-95.
Crossref
Crossref
Maren Vollmer, Mirko Klingebiel, Sascha Rohn & Ronald Maul. (2017) Alamethicin for using in bioavailability studies? – Re-evaluation of its effect. Toxicology in Vitro 39, pages 111-118.
Crossref
Crossref
Peter I. Mackenzie, Andrew A. Somogyi & John O. Miners. (2017) Advances in drug metabolism and pharmacogenetics research in Australia. Pharmacological Research 116, pages 7-19.
Crossref
Crossref
Shufan Ge, Yifan Tu & Ming Hu. (2016) Challenges and Opportunities with Predicting In Vivo Phase II Metabolism via Glucuronidation From In Vitro Data. Current Pharmacology Reports 2:6, pages 326-338.
Crossref
Crossref
Ryoichi Fujiwara, Tsuyoshi Yokoi & Miki Nakajima. (2016) Structure and Protein–Protein Interactions of Human UDP-Glucuronosyltransferases. Frontiers in Pharmacology 7.
Crossref
Crossref
P. C. Nair, R. A. McKinnon & J. O. Miners. (2016) A Fragment-Based Approach for the Computational Prediction of the Nonspecific Binding of Drugs to Hepatic Microsomes. Drug Metabolism and Disposition 44:11, pages 1794-1798.
Crossref
Crossref
Rong Shi, Jiasheng Wu, Cong Meng, Bingliang Ma, Tianming Wang, Yuanyuan Li & Yueming Ma. (2016)
Cyp3a11-mediated testosterone-6β-hydroxylation decreased, while UGT1a9-mediated propofol
O
-glucuronidation increased, in mice with diabetes mellitus
. Biopharmaceutics & Drug Disposition 37:7, pages 433-443.
Crossref
Crossref
Daniel Scotcher, Christopher Jones, Maria Posada, Aleksandra Galetin & Amin Rostami-Hodjegan. (2016) Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part II: Mechanistic Models and In Vitro-In Vivo Extrapolation. The AAPS Journal 18:5, pages 1082-1094.
Crossref
Crossref
Daniel Scotcher, Christopher Jones, Maria Posada, Amin Rostami-Hodjegan & Aleksandra Galetin. (2016) Key to Opening Kidney for In Vitro–In Vivo Extrapolation Entrance in Health and Disease: Part I: In Vitro Systems and Physiological Data. The AAPS Journal 18:5, pages 1067-1081.
Crossref
Crossref
J. Boer, R. Young-Sciame, F. Lee, K. J. Bowman, X. Yang, J. G. Shi, F. M. Nedza, W. Frietze, L. Galya, A. P. Combs, S. Yeleswaram & S. Diamond. (2016) Roles of UGT, P450, and Gut Microbiota in the Metabolism of Epacadostat in Humans. Drug Metabolism and Disposition 44:10, pages 1668-1674.
Crossref
Crossref
Doyun Kim, Yu Fen Zheng, Jee Sun Min, Jung Bae Park, Soo Hyeon Bae, Kee Dong Yoon, Young-Won Chin, Euichaul Oh & Soo Kyung Bae. (2016) In vitro stereoselective inhibition of ginsenosides toward UDP-glucuronosyltransferase (UGT) isoforms. Toxicology Letters 259, pages 1-10.
Crossref
Crossref
Kathleen M. Knights, David M. Stresser, John O. Miners & Charles L. Crespi. (2016) In Vitro Drug Metabolism Using Liver Microsomes. Current Protocols in Pharmacology 74:1.
Crossref
Crossref
Yu Zheng, Jee Min, Doyun Kim, Jung Park, Sung-Wook Choi, Eun Lee, Kun Na & Soo Bae. (2016) In Vitro Inhibition of Human UDP-Glucuronosyl-Transferase (UGT) Isoforms by Astaxanthin, β-Cryptoxanthin, Canthaxanthin, Lutein, and Zeaxanthin: Prediction of in Vivo Dietary Supplement-Drug Interactions. Molecules 21:8, pages 1052.
Crossref
Crossref
T. Bohnert, A. Patel, I. Templeton, Y. Chen, C. Lu, G. Lai, L. Leung, S. Tse, H. J. Einolf, Y.-H. Wang, M. Sinz, R. Stearns, R. Walsky, W. Geng, S. Sudsakorn, D. Moore, L. He, J. Wahlstrom, J. Keirns, R. Narayanan, D. Lang & X. Yang. (2016) Evaluation of a New Molecular Entity as a Victim of Metabolic Drug-Drug Interactions--an Industry Perspective. Drug Metabolism and Disposition 44:8, pages 1399-1423.
Crossref
Crossref
Kathleen M. Knights, Shane M. Spencer, John K. Fallon, Nuy Chau, Philip C. Smith & John O. Miners. (2016)
Scaling factors for the
in vitro
-
in vivo
extrapolation (IV-IVE) of renal drug and xenobiotic glucuronidation clearance
. British Journal of Clinical Pharmacology 81:6, pages 1153-1164.
Crossref
Crossref
Tingting Cai, Lihua Yao & Robert J. Turesky. (2016) Bioactivation of Heterocyclic Aromatic Amines by UDP Glucuronosyltransferases. Chemical Research in Toxicology 29:5, pages 879-891.
Crossref
Crossref
Natacha Lenuzza, Xavier Duval, Grégory Nicolas, Etienne Thévenot, Sylvie Job, Orianne Videau, Céline Narjoz, Marie-Anne Loriot, Philippe Beaune, Laurent Becquemont, France Mentré, Christian Funck-Brentano, Loubna Alavoine, Philippe Arnaud, Marcel Delaforge & Henri Bénech. (2014) Safety and pharmacokinetics of the CIME combination of drugs and their metabolites after a single oral dosing in healthy volunteers. European Journal of Drug Metabolism and Pharmacokinetics 41:2, pages 125-138.
Crossref
Crossref
A. Pattanawongsa, P. C. Nair, A. Rowland & J. O. Miners. (2015) Human UDP-Glucuronosyltransferase (UGT) 2B10: Validation of Cotinine as a Selective Probe Substrate, Inhibition by UGT Enzyme-Selective Inhibitors and Antidepressant and Antipsychotic Drugs, and Structural Determinants of Enzyme Inhibition. Drug Metabolism and Disposition 44:3, pages 378-388.
Crossref
Crossref
Ryo Mitsugi, Kyohei Sumida, Yoshiko Fujie, Robert H. Tukey, Tomoo Itoh & Ryoichi Fujiwara. (2016) Acyl-glucuronide as a Possible Cause of Trovafloxacin-Induced Liver Toxicity: Induction of Chemokine (C-X-C Motif) Ligand 2 by Trovafloxacin Acyl-glucuronide. Biological & Pharmaceutical Bulletin Biological and Pharmaceutical Bulletin 39:10, pages 1604-1610.
Crossref
Crossref
Tony K. L. Kiang & Mary H. H. Ensom. 2016. Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents. Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents
497
534
.
Nan Zhang, Yong Liu & Hyunyoung Jeong. (2015) Drug-Drug Interaction Potentials of Tyrosine Kinase Inhibitors via Inhibition of UDP-Glucuronosyltransferases. Scientific Reports 5:1.
Crossref
Crossref
Kushari Burns, Pramod C. Nair, Andrew Rowland, Peter I. Mackenzie, Kathleen M. Knights & John O. Miners. (2015) The Nonspecific Binding of Tyrosine Kinase Inhibitors to Human Liver Microsomes. Drug Metabolism and Disposition 43:12, pages 1934-1937.
Crossref
Crossref
Karen Rowland-Yeo & Geoffrey T. Tucker. 2015. New Horizons in Predictive Drug Metabolism and Pharmacokinetics. New Horizons in Predictive Drug Metabolism and Pharmacokinetics
283
308
.
J. Matthew Hutzler & Michael A. Zientek. 2015. New Horizons in Predictive Drug Metabolism and Pharmacokinetics. New Horizons in Predictive Drug Metabolism and Pharmacokinetics
79
130
.
Attarat Pattanawongsa, Nuy Chau, Andrew Rowland & John O. Miners. (2015) Inhibition of Human UDP-Glucuronosyltransferase Enzymes by Canagliflozin and Dapagliflozin: Implications for Drug-Drug Interactions. Drug Metabolism and Disposition 43:10, pages 1468-1476.
Crossref
Crossref
Aki T. Heikkinen, Floriane Lignet, Paul Cutler & Neil Parrott. (2015) The role of quantitative ADME proteomics to support construction of physiologically based pharmacokinetic models for use in small molecule drug development. PROTEOMICS - Clinical Applications 9:7-8, pages 732-744.
Crossref
Crossref
Mark Johnson, Shayne Gad & Christopher Kemper. 2015. Animal Models in Toxicology, Third Edition. Animal Models in Toxicology, Third Edition
153
283
.
Jose de Leon. (2015) The effects of antiepileptic inducers in neuropsychopharmacology, a neglected issue. Part II: Pharmacological issues and further understanding. Revista de Psiquiatría y Salud Mental (English Edition) 8:3, pages 167-188.
Crossref
Crossref
Jose de Leon. (2015) Efectos de los inductores antiepilépticos en la neuropsicofarmacología: una cuestión ignorada. Parte II: cuestiones farmacológicas y comprensión adicional. Revista de Psiquiatría y Salud Mental 8:3, pages 167-188.
Crossref
Crossref
Hua Sun, Zhiguo Ma, Danyi Lu & Baojian Wu. (2015) Regio- and Isoform-Specific Glucuronidation of Psoralidin: Evaluation of 3-O-Glucuronidation as a Functional Marker for UGT1A9. Journal of Pharmaceutical Sciences 104:7, pages 2369-2377.
Crossref
Crossref
Nan Wang, Feng Wang, Yu Meng, Guo-Hui Yang, Ju-Wu Chen & Jia-Xiang Wang. (2015) Albumin Supplement Affects the Metabolism and Metabolism-Related Drug-Drug Interaction of Fenoprofen Enantiomers. Chirality 27:7, pages 436-440.
Crossref
Crossref
Li Jiang, Si-Cheng Liang, Chao Wang, Guang-Bo Ge, Xiao-Kui Huo, Xiao-Yi Qi, Sa Deng, Ke-Xin Liu & Xiao-Chi Ma. (2015) Identifying and applying a highly selective probe to simultaneously determine the O-glucuronidation activity of human UGT1A3 and UGT1A4. Scientific Reports 5:1.
Crossref
Crossref
Julieta Gradinaru, Stéphanie Romand, Laurent Geiser, Pierre-Alain Carrupt, Dany Spaggiari & Serge Rudaz. (2015) Inhibition screening method of microsomal UGTs using the cocktail approach. European Journal of Pharmaceutical Sciences 71, pages 35-45.
Crossref
Crossref
Yoichi Naritomi, Fumihiro Nakamori, Takako Furukawa & Kenji Tabata. (2015) Prediction of hepatic and intestinal glucuronidation using in vitro–in vivo extrapolation. Drug Metabolism and Pharmacokinetics 30:1, pages 21-29.
Crossref
Crossref
Xin Liu, Li Sheng, Manman Zhao, Jiaqi Mi, Zhihao Liu & Yan Li. (2015) In?vitro glucuronidation of the primary metabolite of 10-chloromethyl-11-demethyl-12-oxo-calanolide A by human liver microsomes and its interactions with UDP-glucuronosyltransferase substrates. Drug Metabolism and Pharmacokinetics 30:1, pages 89-96.
Crossref
Crossref
R. Meech, N. Mubarokah, A. Shivasami, A. Rogers, P. C. Nair, D. G. Hu, R. A. McKinnon & P. I. Mackenzie. (2014) A Novel Function for UDP Glycosyltransferase 8: Galactosidation of Bile Acids. Molecular Pharmacology 87:3, pages 442-450.
Crossref
Crossref
Lei Wang, ChienWei Chiang, Hong Liang, Hengyi Wu, Weixing Feng, Sara K. Quinney, Jin Li & Lang Li. (2015) How to Choose In Vitro Systems to Predict In Vivo Drug Clearance: A System Pharmacology Perspective. BioMed Research International 2015, pages 1-9.
Crossref
Crossref
Lin-Zhi Chen, John P. Sabo, Elsy Philip, Lois Rowland, Yan Mao, Bachir Latli, Diane Ramsden, Debra A. Mandarino & Rucha S. Sane. (2015)
Mass Balance, Metabolite Profile, and
In Vitro-In Vivo
Comparison of Clearance Pathways of Deleobuvir, a Hepatitis C Virus Polymerase Inhibitor
. Antimicrobial Agents and Chemotherapy 59:1, pages 25-37.
Crossref
Crossref
Andrew Rowland, Peter I. Mackenzie & John O. Miners. (2015) Transporter-Mediated Uptake of UDP–Glucuronic Acid by Human Liver Microsomes: Assay Conditions, Kinetics, and Inhibition. Drug Metabolism and Disposition 43:1, pages 147-153.
Crossref
Crossref
Michael A. Zientek & Kuresh Youdim. (2015) Reaction Phenotyping: Advances in the Experimental Strategies Used to Characterize the Contribution of Drug-Metabolizing Enzymes. Drug Metabolism and Disposition 43:1, pages 163-181.
Crossref
Crossref
Xiang-Ge Tian, Chao Wang, Guang-Bo Ge, Jing Ning, Chun-Zhi Ai, James Y. Hong, Yong-Xv Cai, Xiao-Kui Huo, Jie Hou, Ke-Xin Liu, Hong-Zhi Sun & Xiao-Chi Ma. (2015) A highly selective probe for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human microsomes: isoform specificity, kinetic characterization, and applications. RSC Advances 5:8, pages 5924-5927.
Crossref
Crossref
Seung Jun Lee, Jung Bae Park, Doyun Kim, Soo Hyeon Bae, Young-Won Chin, Euichaul Oh & Soo Kyung Bae. (2015) In vitro selective inhibition of human UDP-glucuronosyltransferase (UGT) 1A4 by finasteride, and prediction of in vivo drug–drug interactions. Toxicology Letters 232:2, pages 458-465.
Crossref
Crossref
N Marsousi, Y Daali, S Rudaz, L Almond, H Humphries, J Desmeules & C F Samer. (2014) Prediction of Metabolic Interactions With Oxycodone via CYP2D6 and CYP3A Inhibition Using a Physiologically Based Pharmacokinetic Model. CPT: Pharmacometrics & Systems Pharmacology 3:12, pages 1-8.
Crossref
Crossref
Kyung-Ah Seo, Hyo-Ji Kim, Eun Sook Jeong, Nagi Abdalla, Chang-Soo Choi, Dong-Hyun Kim & Jae-Gook Shin. (2014) In Vitro Assay of Six UDP-Glucuronosyltransferase Isoforms in Human Liver Microsomes, Using Cocktails of Probe Substrates and Liquid Chromatography–Tandem Mass Spectrometry. Drug Metabolism and Disposition 42:11, pages 1803-1810.
Crossref
Crossref
Kathleen Knights & Arduino Mangoni. 2014. Nutrition and Performance in Masters Athletes. Nutrition and Performance in Masters Athletes
243
262
.
Soo Hyeon Bae, Min Jo Kwon, Jung Bae Park, Doyun Kim, Dong-Hee Kim, Jae-Seon Kang, Chun-Gyu Kim, Euichaul Oh & Soo Kyung Bae. (2014)
Metabolic Drug-Drug Interaction Potential of Macrolactin A and 7-
O
-Succinyl Macrolactin A Assessed by Evaluating Cytochrome P450 Inhibition and Induction and UDP-Glucuronosyltransferase Inhibition
In Vitro
. Antimicrobial Agents and Chemotherapy 58:9, pages 5036-5046.
Crossref
Crossref
Kohei Yamamoto, Marina Mukai, Kenjiro Nagaoka, Keiko Hayashi, Hiroyuki Hichiya, Kenji Okada, Mikio Murata, Masato Shigeyama, Shizuo Narimatsu & Nobumitsu Hanioka. (2014) Functional characterization of cynomolgus monkey UDP-glucuronosyltransferase 1A9. European Journal of Drug Metabolism and Pharmacokinetics 39:3, pages 195-202.
Crossref
Crossref
Kyra J. Barnes, Andrew Rowland, Thomas M. Polasek & John O. Miners. (2014) Inhibition of human drug-metabolising cytochrome P450 and UDP-glucuronosyltransferase enzyme activities in vitro by uremic toxins. European Journal of Clinical Pharmacology 70:9, pages 1097-1106.
Crossref
Crossref
Brahim Achour, Amin Rostami-Hodjegan & Jill Barber. (2014) Protein expression of various hepatic uridine 5′-diphosphate glucuronosyltransferase (UGT) enzymes and their inter-correlations: a meta-analysis. Biopharmaceutics & Drug Disposition 35:6, pages 353-361.
Crossref
Crossref
Su-Lin Liu, Shu-Yao Zhang, Miao-Jun Wang, Hong Jiang, Yu-Xian Yang & Lei Chen. (2013) Demethylzeylasteral exhibits dose-dependent inhibitory behaviour towards estradiol glucuronidation. European Journal of Drug Metabolism and Pharmacokinetics 39:2, pages 99-102.
Crossref
Crossref
Nuy Chau, David J. Elliot, Benjamin C. Lewis, Kushari Burns, Martin R. Johnston, Peter I. Mackenzie & John O. Miners. (2014) Morphine Glucuronidation and Glucosidation Represent Complementary Metabolic Pathways That Are Both Catalyzed by UDP-Glucuronosyltransferase 2B7: Kinetic, Inhibition, and Molecular Modeling Studies. Journal of Pharmacology and Experimental Therapeutics 349:1, pages 126-137.
Crossref
Crossref
Maciej J. Zamek-Gliszczynski, Xiaoyan Chu, Joseph W. Polli, Mary F. Paine & Aleksandra Galetin. (2014) Understanding the Transport Properties of Metabolites: Case Studies and Considerations for Drug Development. Drug Metabolism and Disposition 42:4, pages 650-664.
Crossref
Crossref
Diane Ramsden, Donald J. Tweedie, Roger St. George, Lin-Zhi Chen & Yongmei Li. (2014) Generating an In Vitro–In Vivo Correlation for Metabolism and Liver Enrichment of a Hepatitis C Virus Drug, Faldaprevir, Using a Rat Hepatocyte Model (HepatoPac). Drug Metabolism and Disposition 42:3, pages 407-414.
Crossref
Crossref
Meiyu Wang, Jia Lu, Jiajun Li, Huixin Qi, Yedong Wang & Hongjian Zhang. (2014) Steviol glucuronidation and its potential interaction with UDP-glucuronosyltransferase 2B7 substrates. Food and Chemical Toxicology 64, pages 135-143.
Crossref
Crossref
Daniel R. Albaugh & Michael B. Fisher. 2014. Handbook of Metabolic Pathways of Xenobiotics. Handbook of Metabolic Pathways of Xenobiotics
1
35
.
Rong Shi, Yuanyuan Yang, Jie Zhong, Tianming Wang & Yueming Ma. (2014) Validated assay for the evaluation of multiple glucuronidation activities in human liver microsomes via liquid chromatography-tandem mass spectrometry. RSC Adv. 4:99, pages 56132-56138.
Crossref
Crossref
J.C. Stingl, H. Bartels, R. Viviani, M.L. Lehmann & J. Brockmöller. (2014) Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review. Pharmacology & Therapeutics 141:1, pages 92-116.
Crossref
Crossref
Jin Zhou & John O. Miners. 2014. Enzyme Kinetics in Drug Metabolism. Enzyme Kinetics in Drug Metabolism
203
228
.
Michael H. Court. 2014. Optimization in Drug Discovery. Optimization in Drug Discovery
117
136
.
Jana C. Precht, Werner Schroth, Kathrin Klein, Hiltrud Brauch, Evgeny Krynetskiy, Matthias Schwab & Thomas E. Mürdter. (2013) The Letrozole Phase 1 Metabolite Carbinol as a Novel Probe Drug for UGT2B7. Drug Metabolism and Disposition 41:11, pages 1906-1913.
Crossref
Crossref
Kathleen M. Knights, Andrew Rowland & John O. Miners. (2013)
Renal drug metabolism in humans: the potential for drug–endobiotic interactions involving cytochrome P450 (
CYP
) and
UDP
‐glucuronosyltransferase (
UGT
)
. British Journal of Clinical Pharmacology 76:4, pages 587-602.
Crossref
Crossref
Hua-Mao Jiang, Zhong-Ze Fang, Yun-Feng Cao, Cui-Min Hu, Xiao-Yu Sun, Mo Hong, Ling Yang, Guang-Bo Ge, Yong Liu, Yan-Yan Zhang, Qiang Dong & Ren-Jie Liu. (2013) New insights for the risk of bisphenol A: Inhibition of UDP-glucuronosyltransferases (UGTs). Chemosphere 93:6, pages 1189-1193.
Crossref
Crossref
Martin Perreault, Louis Gauthier-Landry, Jocelyn Trottier, Mélanie Verreault, Patrick Caron, Moshe Finel & Olivier Barbier. (2013) The Human UDP-Glucuronosyltransferase UGT2A1 and UGT2A2 Enzymes Are Highly Active in Bile Acid Glucuronidation. Drug Metabolism and Disposition 41:9, pages 1616-1620.
Crossref
Crossref
Takashi Izumi, Fujiko Tsuruta, Tomoko Ishizuka, Kouichi Nakamura, Masakatsu Kothuma & Takahashi Makoto. (2013) Stereoselectivity in Pharmacokinetics of Rivoglitazone, A Novel Peroxisome Proliferator-Activated Receptor ? Agonist, in Rats and Monkeys: Model-Based Pharmacokinetic Analysis and In Vitro-In Vivo Extrapolation Approach. Journal of Pharmaceutical Sciences 102:9, pages 3174-3188.
Crossref
Crossref
Hyo-Ji Kim, Eun Sook Jeong, Kyung-Ah Seo, Kye Jung Shin, Yeon Jae Choi, Su-Jun Lee, Jong Lyul Ghim, Dong-Ryul Sohn, Jae-Gook Shin & Dong-Hyun Kim. (2013) Glucuronidation of a Sarpogrelate Active Metabolite Is Mediated by UDP-Glucuronosyltransferases 1A4, 1A9, and 2B4. Drug Metabolism and Disposition 41:8, pages 1529-1537.
Crossref
Crossref
Laurent Grosse, Anne-Sophie Campeau, Sarah Caron, Frédéric-Alexandre Morin, Kim Meunier, Jocelyn Trottier, Patrick Caron, Mélanie Verreault & Olivier Barbier. (2013) Enantiomer Selective Glucuronidation of the Non-Steroidal Pure Anti-Androgen Bicalutamide by Human Liver and Kidney: Role of the Human UDP-Glucuronosyltransferase (UGT)1A9 Enzyme. Basic & Clinical Pharmacology & Toxicology 113:2, pages 92-102.
Crossref
Crossref
Jiangbo Du, Tiangeng You, Xiaoyan Chen & Dafang Zhong. (2013) Stereoselective Glucuronidation of Ornidazole in Humans: Predominant Contribution of UDP-Glucuronosyltransferases 1A9 and 2B7. Drug Metabolism and Disposition 41:7, pages 1306-1318.
Crossref
Crossref
Verawan Uchaipichat, Chuthamanee Suthisisang & John O. Miners. (2013) The Glucuronidation of R- and S-Lorazepam: Human Liver Microsomal Kinetics, UDP-Glucuronosyltransferase Enzyme Selectivity, and Inhibition by Drugs. Drug Metabolism and Disposition 41:6, pages 1273-1284.
Crossref
Crossref
Andrew Rowland, John O. Miners & Peter I. Mackenzie. (2013) The UDP-glucuronosyltransferases: Their role in drug metabolism and detoxification. The International Journal of Biochemistry & Cell Biology 45:6, pages 1121-1132.
Crossref
Crossref
Rhiannon N. Hardwick, Daniel W. Ferreira, Vijay R. More, April D. Lake, Zhenqiang Lu, Jose E. Manautou, Angela L. Slitt & Nathan J. Cherrington. (2013) Altered UDP-Glucuronosyltransferase and Sulfotransferase Expression and Function during Progressive Stages of Human Nonalcoholic Fatty Liver Disease. Drug Metabolism and Disposition 41:3, pages 554-561.
Crossref
Crossref
Nenad Manevski, Johanna Troberg, Paolo Svaluto-Moreolo, Klaudyna Dziedzic, Jari Yli-Kauhaluoma & Moshe Finel. (2013) Albumin Stimulates the Activity of the Human UDP-Glucuronosyltransferases 1A7, 1A8, 1A10, 2A1 and 2B15, but the Effects Are Enzyme and Substrate Dependent. PLoS ONE 8:1, pages e54767.
Crossref
Crossref
Mitsuhiro Nishihara, Yuto Hiura, Naohiro Kawaguchi, Junzo Takahashi & Satoru Asahi. (2013) UDP-glucuronosyltransferase 2B15 (UGT2B15) Is the Major Enzyme Responsible for Sipoglitazar Glucuronidation in Humans: Retrospective Identification of the UGT Isoform by In Vitro Analysis and the Effect of UGT2B15*2 Mutation. Drug Metabolism and Pharmacokinetics 28:6, pages 475-484.
Crossref
Crossref
Porntipa Korprasertthaworn, Andrew Rowland, Benjamin C. Lewis, Peter I. Mackenzie, Krongtong Yoovathaworn & John O. Miners. (2012) Effects of amino acid substitutions at positions 33 and 37 on UDP-glucuronosyltransferase 1A9 (UGT1A9) activity and substrate selectivity. Biochemical Pharmacology 84:11, pages 1511-1521.
Crossref
Crossref
Nenad Manevski, Jari Yli-Kauhaluoma & Moshe Finel. (2012) UDP-Glucuronic Acid Binds First and the Aglycone Substrate Binds Second to Form a Ternary Complex in UGT1A9-Catalyzed Reactions, in Both the Presence and Absence of Bovine Serum Albumin. Drug Metabolism and Disposition 40:11, pages 2192-2203.
Crossref
Crossref
Alexander V. LyubimovPeter L. Bullock & Olga V. Trubetskoy. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
26
.
Alexander V. LyubimovKarthik Venkatakrishnan. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
62
.
Alexander V. LyubimovMurali Subramanian & Timothy S. Tracy. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
24
.
Alexander V. LyubimovMurali Subramanian & Timothy S. Tracy. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
27
.
Alexander V. LyubimovRobert S. Foti, Dan A. Rock, Larry C. Wienkers & Jan L. Wahlstrom. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
68
.
Paula S. Montenegro-Miranda, Nina Sneitz, D. Rudi de Waart, Lysbeth ten Bloemendaal, Suzanne Duijst, Robert J. de Knegt, Ulrich Beuers, Moshe Finel & Piter J. Bosma. (2012) Ezetimibe: A biomarker for efficacy of liver directed UGT1A1 gene therapy for inherited hyperbilirubinemia. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1822:8, pages 1223-1229.
Crossref
Crossref
Baojian Wu, Xiaoqiang Wang, Shuxing Zhang & Ming Hu. (2012) Accurate Prediction of Glucuronidation of Structurally Diverse Phenolics by Human UGT1A9 Using Combined Experimental and In Silico Approaches. Pharmaceutical Research 29:6, pages 1544-1561.
Crossref
Crossref
Alexander V. LyubimovRonald E. Savage. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
38
.
Alexander V. LyubimovMichael A. Sinz. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
31
.
Nitsupa Wattanachai, Wichittra Tassaneeyakul, Andrew Rowland, David J. Elliot, Kushari Bowalgaha, Kathleen M. Knights & John O. Miners. (2012) Effect of Albumin on Human Liver Microsomal and Recombinant CYP1A2 Activities: Impact on In Vitro-In Vivo Extrapolation of Drug Clearance. Drug Metabolism and Disposition 40:5, pages 982-989.
Crossref
Crossref
Robert L. Walsky, Jonathan N. Bauman, Karine Bourcier, Georgina Giddens, Kimberly Lapham, Andre Negahban, Tim F. Ryder, R. Scott Obach, Ruth Hyland & Theunis C. Goosen. (2012) Optimized Assays for Human UDP-Glucuronosyltransferase (UGT) Activities: Altered Alamethicin Concentration and Utility to Screen for UGT Inhibitors. Drug Metabolism and Disposition 40:5, pages 1051-1065.
Crossref
Crossref
Eloise A. Gelston, Janet K. Coller, Olga V. Lopatko, Heather M. James, Helmut Schmidt, Jason M. White & Andrew A. Somogyi. (2012) Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects. British Journal of Clinical Pharmacology 73:5, pages 786-794.
Crossref
Crossref
Chun Li & Nataraj Kalyanaraman. 2012. ADME‐Enabling Technologies in Drug Design and Development. ADME‐Enabling Technologies in Drug Design and Development
189
212
.
Liangliang Zhu, Guangbo Ge, Hongbo Zhang, Huixin Liu, Guiyuan He, Sicheng Liang, Yanyan Zhang, Zhongze Fang, Peipei Dong, Moshe Finel & Ling Yang. (2012) Characterization of Hepatic and Intestinal Glucuronidation of Magnolol: Application of the Relative Activity Factor Approach to Decipher the Contributions of Multiple UDP-Glucuronosyltransferase Isoforms. Drug Metabolism and Disposition 40:3, pages 529-538.
Crossref
Crossref
Sheila Annie Peters. 2012. Physiologically‐Based Pharmacokinetic (PBPK) Modeling and Simulations. Physiologically‐Based Pharmacokinetic (PBPK) Modeling and Simulations
183
207
.
Toshifumi Shiraga, Kanako Yajima, Kenta Suzuki, Katsuhiro Suzuki, Tadashi Hashimoto, Takafumi Iwatsubo, Aiji Miyashita & Takashi Usui. (2012) Identification of UDP-Glucuronosyltransferases Responsible for the Glucuronidation of Darexaban, an Oral Factor Xa Inhibitor, in Human Liver and Intestine. Drug Metabolism and Disposition 40:2, pages 276-282.
Crossref
Crossref
V. A. Gruber, P. M. Rainey, D. E. Moody, G. D. Morse, Q. Ma, S. Prathikanti, P. A. Pade, A. A. H. Alvanzo & E. F. McCance-Katz. (2011) Interactions Between Buprenorphine and the Protease Inhibitors Darunavir-Ritonavir and Fosamprenavir-Ritonavir. Clinical Infectious Diseases 54:3, pages 414-423.
Crossref
Crossref
Alexander V. LyubimovDeepak K. Dalvie & Cho‐Ming Loi. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
36
.
Alexander V. LyubimovRobert S. Foti & Michael B. Fisher. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
71
.
Toshifumi Shiraga, Kanako Yajima, Takuya Teragaki, Katsuhiro Suzuki, Tadashi Hashimoto, Takafumi Iwatsubo, Aiji Miyashita & Takashi Usui. (2012) Identification of Enzymes Responsible for the N-Oxidation of Darexaban Glucuronide, the Pharmacologically Active Metabolite of Darexaban, and the Glucuronidation of Darexaban N-Oxides in Human Liver Microsomes. Biological and Pharmaceutical Bulletin 35:3, pages 413-421.
Crossref
Crossref
Yun-Feng Cao, Rong-Rong He, Jun Cao, Jian-Xing Chen, Ting Huang & Yong Liu. (2012) Drug-Drug Interactions Potential of Icariin and Its Intestinal Metabolites via Inhibition of Intestinal UDP-Glucuronosyltransferases. Evidence-Based Complementary and Alternative Medicine 2012, pages 1-8.
Crossref
Crossref
Baojian Wu, Shuxing Zhang & Ming Hu. (2011)
Evaluation of 3,3′,4′-Trihydroxyflavone and 3,6,4′-Trihydroxyflavone (4′-
O
-Glucuronidation) as the in Vitro Functional Markers for Hepatic UGT1A1
. Molecular Pharmaceutics 8:6, pages 2379-2389.
Crossref
Crossref
Tina Trdan Lušin, Jurij Trontelj & Aleš Mrhar. (2011)
Raloxifene Glucuronidation in Human Intestine, Kidney, and Liver Microsomes and in Human Liver Microsomes Genotyped for the
UGT1A1
*
28
Polymorphism
. Drug Metabolism and Disposition 39:12, pages 2347-2354.
Crossref
Crossref
Benjamin C. Lewis, Peter I. Mackenzie & John O. Miners. (2011) Homodimerization of UDP-glucuronosyltransferase 2B7 (UGT2B7) and identification of a putative dimerization domain by protein homology modeling. Biochemical Pharmacology 82:12, pages 2016-2023.
Crossref
Crossref
Nenad Manevski, Paolo Svaluto Moreolo, Jari Yli-Kauhaluoma & Moshe Finel. (2011)
Bovine Serum Albumin Decreases
K
m
Values of Human UDP-Glucuronosyltransferases 1A9 and 2B7 and Increases
V
max
Values of UGT1A9
. Drug Metabolism and Disposition 39:11, pages 2117-2129.
Crossref
Crossref
Anne SoikkeliMika KurkelaJouni HirvonenMarjo YliperttulaMoshe Finel. (2011) Fluorescence-Based High-Throughput Screening Assay for Drug Interactions with UGT1A6. ASSAY and Drug Development Technologies 9:5, pages 496-502.
Crossref
Crossref
Keigo Kosaka, Norifumi Sakai, Yuya Endo, Yuga Fukuhara, Minoru Tsuda-Tsukimoto, Tatsuyuki Ohtsuka, Ichiro Kino, Tomohiko Tanimoto, Naomi Takeba, Masakatsu Takahashi & Toshiyuki Kume. (2011) Impact of Intestinal Glucuronidation on the Pharmacokinetics of Raloxifene. Drug Metabolism and Disposition 39:9, pages 1495-1502.
Crossref
Crossref
James A. McLure, Donald J. Birkett, David J. Elliot, J. Andrew Williams, Andrew Rowland & John O. Miners. (2011) Application of the Fluorescent Probe 1-Anilinonaphthalene-8-Sulfonate to the Measurement of the Nonspecific Binding of Drugs to Human Liver Microsomes. Drug Metabolism and Disposition 39:9, pages 1711-1717.
Crossref
Crossref
Baojian Wu, Kaustubh Kulkarni, Sumit Basu, Shuxing Zhang & Ming Hu. (2011) First-Pass Metabolism via UDP-Glucuronosyltransferase: a Barrier to Oral Bioavailability of Phenolics. Journal of Pharmaceutical Sciences 100:9, pages 3655-3681.
Crossref
Crossref
Yuanchao (Derek) Zhang, Lei Zhang, John M. Strong & Shiew‐Mei Huang. 2011. Oral Bioavailability. Oral Bioavailability
413
429
.
Verawan Uchaipichat, Pritsana Raungrut, Nuy Chau, Benjamas Janchawee, Allan M. Evans & John O. Miners. (2011) Effects of Ketamine on Human UDP-Glucuronosyltransferases In Vitro Predict Potential Drug-Drug Interactions Arising from Ketamine Inhibition of Codeine and Morphine Glucuronidation. Drug Metabolism and Disposition 39:8, pages 1324-1328.
Crossref
Crossref
Baojian Wu, Beibei Xu & Ming Hu. (2011) Regioselective Glucuronidation of Flavonols by Six Human UGT1A Isoforms. Pharmaceutical Research 28:8, pages 1905-1918.
Crossref
Crossref
Nitsupa Wattanachai, Thomas M. Polasek, Tahlia M. Heath, Verawan Uchaipichat, Wongwiwat Tassaneeyakul, Wichittra Tassaneeyakul & John O. Miners. (2011) In vitro–in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6α-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance. European Journal of Clinical Pharmacology 67:8, pages 815-824.
Crossref
Crossref
W. Griffith Humphreys. 2011. Mass Spectrometry in Drug Metabolism and Disposition. Mass Spectrometry in Drug Metabolism and Disposition
229
253
.
John O. Miners, Kushari Bowalgaha, David J. Elliot, Pawel Baranczewski & Kathleen M. Knights. (2011) Characterization of Niflumic Acid as a Selective Inhibitor of Human Liver Microsomal UDP-Glucuronosyltransferase 1A9: Application to the Reaction Phenotyping of Acetaminophen Glucuronidation. Drug Metabolism and Disposition 39:4, pages 644-652.
Crossref
Crossref
Ronald Maul, Diana Siegl & Sabine E. Kulling. (2011) Glucuronidation of the Red Clover Isoflavone Irilone by Liver Microsomes from Different Species and Human UDP-Glucuronosyltransferases. Drug Metabolism and Disposition 39:4, pages 610-616.
Crossref
Crossref
Jiping Wang, Allan M Evans, Kathleen M Knights & John O Miners. (2011) Differential disposition of intra-renal generated and preformed glucuronides: studies with 4-methylumbelliferone and 4-methylumbelliferyl glucuronide in the filtering and nonfiltering isolated perfused rat kidney. Journal of Pharmacy and Pharmacology 63:4, pages 507-514.
Crossref
Crossref
P. I. MacKenzie, A. Rogers, D. J. Elliot, N. Chau, J.-A. Hulin, J. O. Miners & R. Meech. (2010) The Novel UDP Glycosyltransferase 3A2: Cloning, Catalytic Properties, and Tissue Distribution. Molecular Pharmacology 79:3, pages 472-478.
Crossref
Crossref
Jin Zhou, Timothy S. Tracy & Rory P. Remmel. (2011) Correlation between Bilirubin Glucuronidation and Estradiol-3-Gluronidation in the Presence of Model UDP-Glucuronosyltransferase 1A1 Substrates/Inhibitors. Drug Metabolism and Disposition 39:2, pages 322-329.
Crossref
Crossref
Won Young Song, Hye Young Ji, Nam-In Baek, Tae-Sook Jeong & Hye Suk Lee. (2010) In Vitro metabolism of Jaceosidin and characterization of cytochrome P450 and UDP-glucuronosyltransferase enzymes in human liver microsomes. Archives of Pharmacal Research 33:12, pages 1985-1996.
Crossref
Crossref
Karthik Venkatakrishnan, Michael D. Pickard & Lisa L. von Moltke. (2010) A Quantitative Framework and Strategies for Management and Evaluation of Metabolic Drug-Drug Interactions in Oncology Drug Development. Clinical Pharmacokinetics 49:11, pages 703-727.
Crossref
Crossref
Pritsana Raungrut, Verawan Uchaipichat, David J. Elliot, Benjamas Janchawee, Andrew A. Somogyi & John O. Miners. (2010) In Vitro–In Vivo Extrapolation Predicts Drug–Drug Interactions Arising from Inhibition of Codeine Glucuronidation by Dextropropoxyphene, Fluconazole, Ketoconazole, and Methadone in Humans. Journal of Pharmacology and Experimental Therapeutics 334:2, pages 609-618.
Crossref
Crossref
Kathleen M. Knights, Kushari Bowalgaha & John O. Miners. (2010) Spironolactone and Canrenone Inhibit UGT2B7-Catalyzed Human Liver and Kidney Microsomal Aldosterone 18β-Glucuronidation: A Potential Drug Interaction. Drug Metabolism and Disposition 38:7, pages 1011-1014.
Crossref
Crossref
Xiaoxin Qi, Allan M. Evans, Jiping Wang, John O. Miners, Richard N. Upton & Robert W. Milne. (2010) Inhibition of Morphine Metabolism by Ketamine. Drug Metabolism and Disposition 38:5, pages 728-731.
Crossref
Crossref
Hongliang Cai, Nghia Nguyen, Vincent Peterkin, Young-Sun Yang, Kathy Hotz, Deirdre Beaton La Placa, Shujuan Chen, Robert H. Tukey & Jeffrey C. Stevens. (2010)
A Humanized
UGT1
Mouse Model Expressing the
UGT1A1
*
28
Allele for Assessing Drug Clearance by UGT1A1-Dependent Glucuronidation
. Drug Metabolism and Disposition 38:5, pages 879-886.
Crossref
Crossref